Câncer de Pulmão. Benefício e emprego das novas drogas. XIV Congresso da Sociedade Brasileira de Radioterapia
|
|
- Meredith Randall
- 8 years ago
- Views:
Transcription
1 + Câncer de Pulmão Benefício e emprego das novas drogas XIV Congresso da Sociedade Brasileira de Radioterapia Maikol Kurahashi, MD. Oncologia Clínica Hospital Santa Casa de Curitiba
2 Declaração de conflitos de interesse Categorias de Potencial Conflito de Interesse Patrocínio de transporte e/ou hospedagem em Congressos Patrocínio em estudos clínicos e/ou experimentais subvencionados pela indústria Ser conferencista/palestrante em eventos patrocinados pela indústria Participar de comitês normativos de estudos científicos patrocinados pela indústria Indústria(s) Novartis, Pfizer, Roche, GSK, Merck Serono, Lilly Roche, Pierre- Fabre, Morphotek Pfizer, Roche, Novartis Não Receber apoio institucional da indústria Não Preparo de textos científicos em periódicos patrocinados pela indústria Não Ter ações da indústria Não CFM n 1.595/00 de 18/05/2000
3 + Principal causa de morte por câncer em todo mundo óbitos anualmente EUA em 2010: casos novos e óbitos Brasil em 2010: casos novos
4 SCLC NSCLC + Adenocarcinoma Carcinoma Epidermóide Carcinoma de grandes células
5 + Incidence of NSCLC Histologic Subtypes 15% 20% 40% Adenocarcinoma Squamous-cell carcinoma Large-cell carcinoma NOS 30% American Cancer Society.
6 + The role of chemoteraphy Surgery, Radiotherapy, Chemotherapy vs. BSC 9387 patients (7151 deaths) from 52 randomised clinical trials C vs. NoC:11 trials (1190 patients and 1144 deaths) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ1995;311:
7 + Chemotherapy vs Best Supportive Care in Advanced NSCLC: Meta-Analysis Meta-analysis of 8 trials (778 patients) using cisplatin-based chemotherapy [1] Absolute improvement in survival of 10% at 1 yr [1] Median survival, BSC vs chemo: 4 vs 8+ mos, respectively Median survival now 12+ mos in more recent trials VEGF-targeted therapy plus platinum doublet [2] Quality-of-life benefit from chemotherapy [3] 1. NSCLC Collaborative Group, et al. BMJ. 1995;311: Herbst R, et al. Clin Lung Cancer. 2009;10: Klastersky J, et al. Lung Cancer. 2001;34(suppl 4):S95-S101.
8 + One Size Fits All
9 +
10 + A histologia faz a diferença Adenocarcinoma Carcinoma Epidermóide Carcinoma de grandes células
11 + CONSORT: Phase III Gemcitabine or Pemetrexed + Cisplatin as First-line Therapy Advanced-stage, previously untreated NSCLC patients (N = 1725) Stratified by: ECOG PS (0 vs 1) Cisplatin 75 mg/m 2 on Day 1 Gemcitabine 1250 mg/m 2 on Days 1 and 8 Six 3-wk cycles Cisplatin 75 mg/m 2 on Day 1 Pemetrexed 500 mg/m 2 on Day 1 Six 3-wk cycles Disease stage (IIIB vs IV) Brain metastases (yes vs no) Sex (male vs female) Pathologic diagnosis (histologic vs cytologic) Treatment center Scagliotti GV, et al. J Clin Oncol. 2008;26:
12 + JMDB Trial: Cisplatin/Pemetrexed vs Cisplatin/Gemcitabine in Advanced NSCLC No difference in OS or PFS between study arms Cis/pem improves OS over cis/gem in non-scca (HR: 0.81; P =.005) Cis/gem improves OS over cis/pem in SCCA (HR: 1.23; P =.05) Scagliotti GV, et al. J Clin Oncol. 2008;26: Survival Probability Survival Probability Survival Probability CP CG 0.6 CP vs CG Survival Time (Mos) in All Patients CP CG 0.6 CP vs CG Survival Time (Mos) in Patients With Nonsquamous Histology CP CG 0.6 CP vs CG Survival Time (Mos) in Patients With Squamous Histology Median (95% CI) 10.3 ( ) 10.3 ( ) Adjusted HR (95% CI) 0.94 ( ) Median (95% CI) 11.8 ( ) 10.4 ( ) Adjusted HR (95% CI) 0.81 ( ) Median (95% CI) 9.4 ( ) 10.8 ( ) Adjusted HR (95% CI) 1.23 ( )
13 + CONSORT: Efficacy Survival Pemetrexed + Cisplatin (n = 862) Gemcitabin e + Cisplatin (n = 863) HR (95% CI) P Value Median OS, mos ( ) Noninferi or Adenocarcinoma (N = 847) ( ).03 Large-cell carcinoma (N = 153) ( ).03 Squamous cell carcinoma (N = 473) ( ).05 Scagliotti GV, et al. J Clin Oncol. 2008;26:
14 + Cancer Paradigm 2012 Tumors Genes Targets Drugs
15
16 Lung Cancer Mutation Consortium Incidence of Single Driver Mutations
17 + Algorithm for Therapy of Advanced Stage NSCLC: 2012 Proposed treatment algorithm EGFR mutation positive or ALK fusion positive Molecular Good PS Clinical (PS) Poor PS Erlotinib or Crizotinib Nonsquamous Histologic Squamous Single-agent chemotherapy Bevacizumab eligible Platinum/pemetrexed (or other*) ± bevacizumab Clinica l Bevacizumab ineligible Platinum/pemetrexed (or other*) Platinum doublet plus cetuximab? First line Progression Chemotherapy by algorithm Bevacizumab or erlotinib or pemetrexed Based on prior therapy End of first-line chemotherapy Pemetrexed or erlotinib Based on prior therapy Erlotinib? Based on prior therapy Based on prior therapy Maintenance Second line *Docetaxel, paclitaxel, or vinorelbine. Adapted from Gandara DR, et al. Clin Lung Cancer. 2009;10:
18 + Mabs Tkis Bevacizumab Cetuximab Erlotinib Gefitinib Crizotinib
19 VEGF: Targeted Approaches - Antibody Bevacizumab Anti-receptor blocking antibodies Tyrosine kinase inhibitors Antiligand blocking antibodies Adapted from Noonberg and Benz. Drugs. 2000;59:753.
20 Bevacizumab in Advanced NSCLC Phase III ECOG patients: Carboplatin/Paclitaxel +/- Bevacizumab PFS 6.2 vs 4.5 mo, response 35% vs 15% OS 12.3 mo (10.3 mo control) Phase III AVAiL 1043 patients: Cisplatin/Gemcitabine +/- Bevacizumab PFS HR 0.75, p.003 at 7.5 mg/kg 0.85, p.046 at 15 mg/kg RR 32% vs 20% OS 13.6m (7.5); 13.4m (15); 13.1m (plac), NS Johnson. JCO. 22:184-91, 2004, Sandler. NEJM. 355: , 2006, Manegold. ASCO. 2007, abstr LBA 7514.
21 E4599: Phase III Carbo/Paclitaxel +/- Bevacizumab Patients with recurrent or advanced stage IIIb/IV NSCLC and no previous chemotherapy Paclitaxel 200 mg/m 2 + Carboplatin AUC 6 (PC) q3w 6 (no crossover permitted) (N = 878) Bevacizumab + 15 mg/kg q3w + PC 6 Bevacizumab until PD or unacceptable toxicity (n = 215; 53%) Of the 407 patients starting treatment with paclitaxel and carboplatin plus bevacizumab for whom we had adequate data on the duration of treatment, 215 patients (53%) continued with bevacizumab monotherapy, and of these, 107 (50%) received more than 5 cycles of monotherapy Sandler A, et al. N Engl J Med. 2006;355:
22 E4599: Carboplatin/Paclitaxel ± Bevacizumab Carboplatin/paclitaxel Carboplatin/paclitaxel + bevacizumab 100 PFS 100 OS PFS (%) P <.001; HR: 0.66 Median PFS: 6.2 vs 4.5 mos OS (%) P =.003; HR: 0.79 Median OS: 12.3 vs 10.3 mos Mos Mos Sandler A, et al. N Engl J Med. 2006;355:
23 Bevacizumab in Advanced NSCLC Phase III ECOG patients: Carboplatin/Paclitaxel +/- Bevacizumab PFS 6.2 vs 4.5 mo, response 35% vs 15% OS 12.3 mo (10.3 mo control) Phase III AVAiL 1043 patients: Cisplatin/Gemcitabine +/- Bevacizumab PFS HR 0.75, p.003 at 7.5 mg/kg 0.85, p.046 at 15 mg/kg RR 32% vs 20% OS 13.6m (7.5); 13.4m (15); 13.1m (plac), NS Johnson. JCO. 22:184-91, 2004, Sandler. NEJM. 355: , 2006, Manegold. ASCO. 2007, abstr LBA 7514.
24 Possibility of PFS (%) PFS Endpoint CG + Placebo AVAiL: Efficacy Results Mos CG + Bevacizumab (7.5 mg/kg) CG + Bevacizumab (15 mg/kg) PFS, HR (95% CI; P value) NA 0.75 ( ;.0026) 0.82 ( ;.0301) RR, % (P value) (<.0001) 30 (<.017) Median survival, mos HR (P value) CG + placebo CG + bevacizumab 7.5 mg/kg 13.1 (-) 1. Reck M, et al. J Clin Oncol. 2009;27: Reck M, et al. Ann Oncol. 2010;21: PFS (.3664) CG + placebo CG + bevacizumab 15 mg/kg Mos (.8420)
25 Bevacizumab in Special Populations: Summary Caution with elderly patients; ongoing trials Hemoptysis remains an issue, but anticoagulation can be considered cautiously Safe in patients with treated brain metastases Squamous histology still a major bleeding risk
26 Cetuximab Background Monoclonal anti-egfr IgG1 antibody Inhibits EGFR signaling Effective across several solid tumors, improving overall survival in mcrc (Van Cutsem E. J Clin Oncol, 2011) SCCHN (Bonner JA. N Engl J Med, 2006 and Lancet Oncol, 2009; Vermorken J. N Engl J Med, 2008) Advanced NSCLC (Pirker R. Lancet, 2009) In first-line treatment of advanced NSCLC, cetuximab significantly increased OS when added to cisplatin/vinorelbine (phase III FLEX) (Pirker R. Lancet, 2009) EGFR = epidermal growth factor receptor; ADCC = antibody-dependent cell-mediated cytotoxicity; mcrc = metastatic colorectal cancer; SCCHN = squamous cell carcinoma of the head and neck; NSCLC = non-small cell lung cancer
27 FLEX: Chemotherapy ± Cetuximab in First-line Therapy of Advanced NSCLC Stage IIIB or IV EGFR positive R Cetuximab + Cisplatin + Vinorelbine (n = 557) Survival Cisplatin + Vinorelbine (n = 568) Eligibility criteria: EGFR-expressing, advanced-stage NSCLC; no previous CT Primary endpoint: median OS (845 events needed) Secondary endpoints: survival rate (1 and 2 yrs), PFS rate (6 and 12 mos), response rate, safety, QoL Sample size: 1125 in 155 centers in EU, Latin America, Asia Pirker R, et al. Lancet. 2009;373:
28 Rationale for EGFR Expression Analysis as Continuous Variable: Results from FLEX: ITT Analysis of OS Overall Survival (%) 10.1 mo CT + Cetuximab (n = 557) CT (n = 568) 11.3 mo HR = (95% CI ) P = year OS: 47% vs 42% Pirker (months) No at risk CT CT + Cetuximab Pirker R, et al. Lancet, 2009 P value = stratified log-rank test (2-sided)
29 FLEX: Response Rate by EGFR Expression Levels (IHC Score) Low EGFR Expression (< 200) (n = 776) (69%) High EGFR Expression ( 200) (n = 345) (31%) Response Rate (%) Response Rate (%) P =.36 P =.002 CT + cetuximab CT Treatment interaction test p =.040 O Byrne K, et al. JTO. 2010;12(suppl): S558 (LBOA1).
30 Predictive Value of High EGFR for Survival Benefit With CT + Cetuximab OS (%) Low EGFR Mos Interaction P =.044 High EGFR HR: 0.99 (95% CI: ) HR: 0.73 (95% CI: ) OS (%) CT + cetuximab CT Mos Pirker R, et al. IASLC WCLC Abstract O01.06
31 + Epidermal Growth Factor Receptor Mutations
32 + Início do uso de TKIs Gefitinib Descoberta do alvo Biomarcador Mutação do EGFR
33 + First-line treatment of EGFR-mutant NSCLC EGFR mutant EGFR TKI 1. Is EGFR TKI monotherapy better than chemo? 2. What about combinations of TKI and chemo? 3. Are all the mutants the same? 4. Why are responses to EGFR TKIs heterogenous? 5. What pathways are driving (relative) resistance?
34 + IPASS: Gefitinib vs Carboplatin/Paclitaxel in Select Patients With Advanced NSCLC Randomized from March 2006 to October 2007 Up to six 3-wk cycles Previously untreated patients with stage IIIB/IV NSCLC; never or light ex-smokers; PS 0-2 (N = 1217) Gefitinib 250 mg/day PO (n = 609) Paclitaxel 200 mg/m 2 IV on Day 1 + Carboplatin AUC 5-6 mg/ml/min IV on Day 1 (n = 608) Primary endpoint: PFS (noninferiority) Secondary endpoints: ORR, OS, QoL, safety, disease-related symptoms Exploratory endpoints: EGFR mutation, EGFR gene copy number, EGFR protein expression Mok TS, et al. N Engl J Med. 2009;361:
35 + IPASS: Results in ITT Population 1.0 PFS 1.0 OS* Probability of PFS Mos G C/P n Median PFS, mos Gefitinib Carboplatin/paclitaxel HR: 0.74; P < mo PFS, % 25 7 Mok TS, et al. N Engl J Med. 2009;361: Probability of Survival Mos G C/P ORR, % Median OS, mos Gefitinib Carboplatin/paclitaxel *Follow-up ongoing HR: 0.91; P = NR 12-mo OS, % 68 64
36 + IPASS: PFS in EGFR Mutation Probability of PFS Positive vs Negative Patients EGFR Mutation Positive Gefitinib (n = 132) Carboplatin/paclitaxel (n = 129) HR: 0.48 (95% CI: ) P <.001 No. events gefitinib,: 97 (73.5%) No. events C/P,: 111 (86.0%) Mos At risk: Gefitinib C/P Treatment by subgroup interaction test, P <.001 Incidence of EGFR mutation on IPASS participants: 261/437 (59.7%) Mok TS, et al. N Engl J Med. 2009;361: Probability of PFS EGFR Mutation Negative Gefitinib (n = 91) Carboplatin/paclitaxel (n = 85) HR: 2.85 (95% CI: ) P <.001 No. events gefitinib: 88 (96.7%) No. events C/P: 70 (82.4%) Mos
37 + OPTIMAL study design Phase III study initiated by Tongji University, Shanghai, China Recruitment ongoing in China Chemo-naїve advanced NSCLC (N~150) EGFR mutation positive (exon 19 or 21) ECOG PS 0 2 Primary endpoint R 1:1 Erlotinib 150 mg/day until PD Gemcitabine + carboplatin (1,000 mg/m 2 d1, 8; AUC5 d1) q3w, up to 4 cycles PFS Secondary endpoints OS, ORR, QoL and safety
38 + OPTIMAL: 1 st -line erlotinib is associated with longer PFS vs GC in EGFR-mutant NSCLC Zhou, You, Lancet Oncology 2011
39 + EURTAC study design Phase III study initiated by the Spanish Lung Cancer Group (GECP) Recruitment ongoing in Spain, Italy and France Chemo-naїve advanced NSCLC EGFR mutation positive (exon 19 or L858R) ECOG PS 0 2 (n~150) R 1:1 Erlotinib 150 mg/day until PD Platinum-based doublet chemotherapy Primary endpoint PFS Secondary endpoints ORR, 1-year survival, OS, safety, QoL, localization of PD
40 + EURTAC: First-line Erlotinib vs Chemo in European Patients With EGFR Mutations 174 patients Trial run in Europe (lead by Spanish group) Outcome CT Erlotinib HR P Value Response rate, % NR Median PFS, mos <.0001 Median OS, mos NR NR Most common toxicities, % ALT elevation: 72 Anemia: 46 Neutropenia: 36 ALT elevation: 80 Rash: 80 Diarrhea: 57 Rosell R, et al. ASCO Abstract 7503.
41 + EURTAC: PFS in ITT Population PFS Probability Patients at Risk, n Erlotinib Chemo Erlotinib (n = 86) Chemotherapy (n = 87) HR: 0.37 (95% CI: ; log-rank P <.0001) Mos Rosell R, et al. ASCO Abstract 7503.
42 + EURTAC vs Asian Trials in EGFR Mutated NSCLC: RR and PFS Study Response Rate, % PFS, Mos (HR) EURTAC 58.0 vs vs 5.2 (0.37) OPTIMAL 83 vs vs 4.6 (0.16) NEJ vs vs 5.4 (0.30) WJTOG vs vs 6.3 (0.49) None of the EGFR-TKI vs chemo as first-line therapy trials in EGFR mut NSCLC have shown a significant OS benefit Rosell R, et al. J Clin Oncol. 2011;29(suppl). Abstract 7503.
43 + Summary: First-line treatment of EGFRmutant NSCLC Which mutant? EGFR mutant T790M? Other markers? 1. EGFR monotherapy is a standard. PFS for TKI is better than chemo. Addition of chemo not beneficial thus far. 2. All mutants are not the same. 3. We may be missing baseline T790M should we be using combinations for these patients at onset? Or different TKIs? 4. In the future, other markers (e.g. IGF-1R) may predict worse outcome combination Rx?
44 +
45 +
46 +
47 +
48 +
49 +
50 +
51 EML4-ALK Translocations in NSCLC EML4 1 HELP Basic WD EML4-ALK frequency: ~ 4% (64/1709) EML4-ALK variant Primarily in adenocarcinoma More common in younger patients ALK TM Kinase More common in never-smokers
52 Crizotinib: First-in-human ALK Inhibitor Potent and selective ATP competitive oral inhibitor of ALK and MET tyrosine kinases and their oncogenic variants Crizotinib (PF ) Safety and activity of crizotinib examined in an expanded cohort of patients with advanced ALK-positive NSCLC 1 Crizotinib administered at the MTD of 250 mg PO twice daily 1 Kwak et al. NEJM 2010;363: Shaw ASCO 2011, Lancet Oncology 12:1004, 2011
53 + Tumor Responses to Crizotinib for Maximum change in tumor size (%) Patients with ALK-positive NSCLC % Progressive disease Stable disease Confirmed partial response Confirmed complete response 100 * Bang ASCO plenary 2010, Kwak NEJM 2010 N= 76
54 Crizotinib Summary Crizotinib highly effective in pts w/ ALK FISH+ NSCLC Better diagnostics under development Survival benefit demonstrated Role as 1 st line therapy under investigation Currently in NCCN guidelines Resistance in < 1 yr a major issue Mechanisms, 2 nd mutations, growth of other clones
55 + c-met as a Therapeutic Target in NSCLC HGF/MET axis is associated with invasiveness and is regulated in part by the HIF and EGFR pathways MET amplifications are associated with EGFR inhibitor resistance HGF/MET may promote resistance to VEGF inhibitors Xu L, et al. Oncogene. 2010;29: Engelman JA, et al. Science. 2007;316: Cascone, et al. ASCO 2010.
56 + c-met receptor tyrosine kinase inhibitors promising therapeutic target in NSCLC ARQ-197, a novel and selective non-atp competitive inhibitor of c-met ARQ 209 enrolled 167 advanced NSCLC patients Randomized, placebo-controlled, double-blind clinical trial NSCLC Inoperable locally adv/metastatic dz. 1 prior chemo (no prior EGFR TKI) Endpoints Primary: PFS Secondary: ORR, OS Subset analyses Crossover: ORR R A N D O M I Z E 33 sites in 6 countries Erlotinib 150 mg PO QD + ARQ mg PO BID 28-day cycle Erlotinib 150 mg PO QD + Placebo 28-day cycle Study accrual over 11 months (10/08 9/09) PD Randomization stratified by prognostic factors including sex, age, smoking, histology, performance status, prior therapy, best response, and geography (US vs ex-us) Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
57 + ARQ-197 plus erlotinib was associated with improvements in PFS and OS compared with erlotinib alone PFS (ITT population) Overall survival (ITT population) *Cox regression model. Schiller JH, et al. J Clin Oncol 2010;28:18s (abstr LBA7502 and oral presentation)
58 + EPIC: Prospective Validation of ERCC1, RRM1, TS 2:1 Randomization Individualized arm Control arm EGFR mut + Squamous cell carcinoma Treatment based on investigators preference Yes Yes No EGFR mut + Yes Off study ERCC1 low RRM1 high ERCC1 high RRM1 low ERCC1 low RRM1 low ERCC1 high RRM1 high No Carboplatin Gemcitabine Carbo/gem Taxane ERCC1 low TS high ERCC1 high TS low ERCC1 low TS low ERCC1 high TS high Carboplatin Pemetrexed Carbo/pem PIs : G. Simon & G. Scagliotti University of South Carolina (Hollings Cancer Center) & University of Torino RRM1 low Gemcitabine RRM1 high Taxane
59 Figure 6 Source: Cell, Volume 144, Issue 5, Pages (DOI: /j.cell ) Copyright 2011 Elsevier Inc. Terms and Conditions
60
61 Riess JW, Wakelee HA. Clinical Advances in Hematology & Oncology Volume 10, Issue 4 April 2012
62 + History of Therapy in Advanced NSCLC: FDA Approval Dates First line Second line Third line Maintenance Not approved *Label does not include NSCLC-specific indication Cisplatin* 1978 ~ 2-4 Standard therapies Carboplatin* 1989 Vinorelbine ~ 6 Docetaxel 1999 Paclitaxel Gemcitabine 1998 Docetaxel 2002 BSC Single-agent platinum Doublets ~ 8-10 Gefitinib 2003 Erlotinib Pemetrexed 2004 Bevacizumab Pemetrexed 2008/2009 Median OS (mos) IPASS: 18.8m Bevacizumab + PC Histology-directed therapy 1. FDA Web site. 2. NCCN. Clinical practice guidelines in oncology. v Schrump, et al. Non-small cell lung cancer. In: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationEGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004
Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationThorakale Onkologie. ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013
Triple negativ Thorakale Onkologie ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013 Driver Oncogene Mutations in non sq-nsclc Genome Res. 2012 November; 22(11): 2109 2119 8021: Detection of EGFR-activating
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationUpdate on Targeted Therapies of NSCLC
Update on Targeted Therapies of NSCLC Tanja Cufer, MD, PhD University Clinic Golnik Medical Faculty Ljubljana, Slovenia Bled 2014 1 Systemic Therapy of Advanced NSCLC: Chemotherapy Range Cht improves survival
More informationTargeted agents in lung cancer: EGFR TKI and beyond
Targeted agents in lung cancer: EGFR TKI and beyond David CL Lam, MBBS, PhD, MD, FCCP, FACP, FRCP, FAPSR Clinical Assistant Professor Department of Medicine University of Hong Kong 13 Nov, 2014 The Changing
More informationnon-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas
Adjuvant chemotherapy for non-small-cell lung cancer Quimioterapia adjuvante para câncer de pulmão não pequenas células Daniel B. Costa, MD, PhD, MMSc Division i i of Hematology/Oncology l Beth Israel
More informationLung cancer is the leading cause of cancer-related death in the United
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer MARGARET E. M. VAN METER, MD Medical Oncology Fellow Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston,
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationStato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare
Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare Giorgio V. Scagliotti Università di Torino Dipartimento di scienze cliniche & biologiche giorgio.scagliotti@unito.it
More informationNON-SMALL CELL LUNG CANCER STAGE IV
NON-SMALL CELL LUNG CANCER STAGE IV Effective Date: November, 2013 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationSYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1
More informationPiano Generale di Emergenza Presidio Ospedaliero di Livorno Viale Alfieri 36
Aprile 2011 EGFR-TKIs for the treatment of advanced NSCLC with EGFR mutations Piano Generale di Emergenza Presidio Ospedaliero di Livorno Viale Alfieri 36 Federico Cappuzzo Istituto Toscano Tumori Ospedale
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationEvolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICE NEWS.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer CALEB T. CHU, MD, MPH Postdoctoral Fellow Department of Thoracic/Head and Neck Medical Oncology
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationPulmonary and Critical Care Regional Symposium April 25, 2015
Pulmonary and Critical Care Regional Symposium April 25, 2015 2015: Molecular Medicine, Resistance Mutations and Immunotherapy. Keeping Up With The Latest in NSCLC Barbara J. Gitlitz MD Associate Professor
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationLessons learned from gefitinib and crizotinib clinical trials in NSCLC
Lessons learned from gefitinib and crizotinib clinical trials in NSCLC Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital affiliated to Jiao Tong University New Era of Cancer Care: Genomic Era
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationCurrent Progress for Non-Small Cell Lung Cancer Treatment
Chemotherapy : Mechanisms of Action Current Progress for Non-Small Cell Lung Cancer Treatment Topo inhibitors Alkylators CHR Tubulin active agents Topo I,II Pt Wen-Pin Su, M.D./ Prof. Wu-Chou Su National
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationClinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
More informationChemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status
Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status Tracey L. Evans, MD Abstract In spite of advances in molecular profiling
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationTargeted Therapy for Lung Cancer: The Greater Impact in the New Era
Targeted Therapy for Lung Cancer: The Greater Impact in the New Era Fadlo Raja Khuri, MD Professor and Roberto C. Goizueta Chair Department of Hematology & Medical Oncology Deputy Director Winship Cancer
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationCáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta
Cáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Advanced NSCLC: chemotherapy has reached a therapeutic
More informationTreatment of Stage IV Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest
More informationTailoring Treatment Plans to Improve Outcomes in the Management of NSCLC
Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC Martin J. Edelman, MD 1 Educational Objectives Review efficacy and safety data for current and emerging targeted agents and chemotherapy
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationMedical Policy Manual. Date of Origin: August 2010. Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC)
Medical Policy Manual Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC) Section: Genetic Testing Policy No: 56 Date of Origin: August 2010 Last Reviewed Date: December
More informationPersonalizing Treatment for NSCLC
Educational Objectives At the conclusion of this activity, participants should be able to demonstrate the ability to: Review strategies for molecular evaluation of NSCLC Discuss formulation of treatment
More informationSecond-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
VOLUME 32 NUMBER 18 JUNE 20 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens Alona Zer and Natasha
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationSystemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VI. THERAPY. III. TARGETED THERAPY FOR NON SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VI. THERAPY. III. TARGETED THERAPY FOR NON SMALL CELL LUNG CANCER Prof. Alberto Riccardi Targeted therapies. I. Signaling pathways
More informationElderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?
4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,
More informationDr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating?
Dr Peter Briggs Medical Oncologist Lung Cancer & Mesothelioma: is it worth treating? GOALS OF CANCER THERAPY CURE Good chance Medium chance Low chance PALLIATION Life prolonging Symptomatic improvement
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationMechanisms of primary/secondary resistance to EGFR inhibitors
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Mechanisms of primary/secondary resistance to EGFR inhibitors Silvia Novello University of Torino Italy Department of Oncology silvia.novello@unito.it www.womengainstlungcancer.eu
More informationTreatment Paradigms in Advanced Non Small-Cell Lung Cancer
Treatment Paradigms in Advanced Non Small-Cell Lung Cancer Caroline E. McCoach, MD, PhD, and Karen Kelly, MD Dr McCoach is a clinical research fellow and Dr Kelly is a professor of medicine, an associate
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationLung cancer remains the leading cause of cancer-related death in the. Evolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT CLINICALONCOLOGY.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer KATHRYN F. MILEHAM, MD Staff Oncologist HEATHER D. BROOKS, MD Staff Oncologist EDWARD S. KIM,
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationNieuwe patientenselectie met longcarcinoom als rolmodel voor de medisch oncoloog
Nieuwe patientenselectie met longcarcinoom als rolmodel voor de medisch oncoloog Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands ASCO 2013
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationPublished Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923. J Clin Oncol 29. 2011 by American Society of Clinical Oncology
Published Ahead of Print on April 11, 2011 as 10.1200/JCO.2010.31.8923 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.31.8923 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationImmuno-Oncology 2015: A New Landscape in Lung Cancer
Immuno-Oncology 2015: A New Landscape in Lung Cancer David R. Spigel, M.D. Lung Cancer Program Director Sarah Cannon Research Institute/Tennessee Oncology, PLLC Nashville, TN Off-Label Use Disclosure(s)
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationGenomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationNON-SMALL CELL LUNG CANCER
NON-SMALL CELL LUNG CANCER Executive Summary In 2012, an estimated 1.8 million people were diagnosed with lung cancer resulting in 1.6 million deaths (http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx).
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationThe role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationNational Clinical Trials Network Groups Update Fall 2014
National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update
More informationFollow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationHighlights in NSCLC From the 15th World Conference on Lung Cancer
January 214 Volume 12, Issue 1, Supplement 1 A SPECIAL MEETING REVIEW EDITION Highlights in CLC From the 15th World Conference on Lung Cancer A Review of Selected Presentations From the 15th World Conference
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More information